BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 7707383)

  • 1. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil.
    Sela S; Husain SR; Pearson JW; Longo DL; Rahman A
    J Natl Cancer Inst; 1995 Jan; 87(2):123-8. PubMed ID: 7707383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
    Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
    Rahman A; Husain SR; Siddiqui J; Verma M; Agresti M; Center M; Safa AR; Glazer RI
    J Natl Cancer Inst; 1992 Dec; 84(24):1909-15. PubMed ID: 1361008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody.
    Pearson JW; Fogler WE; Volker K; Usui N; Goldenberg SK; Gruys E; Riggs CW; Komschlies K; Wiltrout RH; Tsuruo T
    J Natl Cancer Inst; 1991 Oct; 83(19):1386-91. PubMed ID: 1681110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
    Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
    J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein.
    Matsuo H; Wakasugi M; Takanaga H; Ohtani H; Naito M; Tsuruo T; Sawada Y
    J Control Release; 2001 Nov; 77(1-2):77-86. PubMed ID: 11689261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
    Naito M; Tsuge H; Kuroko C; Koyama T; Tomida A; Tatsuta T; Heike Y; Tsuruo T
    J Natl Cancer Inst; 1993 Feb; 85(4):311-6. PubMed ID: 7678867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.
    Oudard S; Thierry A; Jorgensen TJ; Rahman A
    Cancer Chemother Pharmacol; 1991; 28(4):259-65. PubMed ID: 1678995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
    Stein U; Walther W; Shoemaker RH
    J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin.
    Sadasivan R; Morgan R; Fabian C; Stephens R
    Cancer Lett; 1991 May; 57(2):165-71. PubMed ID: 1673873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance by an immunosuppressive agent FK-506.
    Naito M; Oh-hara T; Yamazaki A; Danki T; Tsuruo T
    Cancer Chemother Pharmacol; 1992; 29(3):195-200. PubMed ID: 1370765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
    Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
    Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.
    Tsuruo T; Iida H; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1983 Feb; 43(2):808-13. PubMed ID: 6848194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts.
    Boven E; Jansen WJ; Hulscher TM; Beijnen JH; van Tellingen O
    Eur J Cancer; 1999 May; 35(5):840-9. PubMed ID: 10505047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.
    Naito S; Koike K; Ono M; Machida T; Tasaka S; Kiue A; Koga H; Kumazawa J
    Oncol Res; 1998; 10(3):123-32. PubMed ID: 9700723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin.
    Thierry AR; Jorgensen TJ; Forst D; Belli JA; Dritschilo A; Rahman A
    Cancer Commun; 1989; 1(5):311-6. PubMed ID: 2577154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.
    Chiang CD; Song EJ; Yang VC; Chao CC
    Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):759-64. PubMed ID: 7914401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes.
    Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A
    FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules.
    Dassow H; Lassner D; Remke H; Preiss R
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):209-16. PubMed ID: 10783831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.